R&D
- Aesthetics
Localized Fat Reduction, Cellulite,
Hyperpigmentation, Skin Aging
- Therapeutics
Dercum's Disease, Osteoarthritis, Central Obesity
-
Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/
Market
Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/
Market -
Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/
Market
Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/
Market -
Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/
Market
Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/
Market -
Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/
Market
Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/
Market
-
CBL-514
-
CBA-539
-
CBO-012
-
CBF-520
-
CBL-539, a long-acting injectable product, is designed for a more efficacious and safe treatment for refractory melasma by inhibiting melanin production. Besides, CBL-539 was evidenced that could recover skin elasticity by increasing collagen production.
Conditions/Indications： Hyperpigmentation, Skin aging
About Caliway
In Caliway, we are driven to breakthrough drug discovery of novel small-molecule therapeutics for medical aesthetics and inflammatory disease. By developing innovative drugs, we aim to provide new treatment options for the indications in which clinical needs remain unmet.
-
ADVANTAGE
Well-Experimented Team of Experts
Caliway's research team comprises experts with deep knowledge and experience in drug discovery, business development, and regulatory affairs. We develop innovative new strategies with high safety to address medical conditions with no effective treatments available. -
ADVANTAGE
Target Emerging Markets
In Caliway, the diseases we are targeted on affect millions of people, often in their most productive years. We are on a mission to combine science, medicine, and advocacy with improving people's lives suffering from illnesses or life-threatening diseases. -
ADVANTAGE
Global IP Protection
We have exclusive rights to benefit from the commercial use of our products, such as producing, selling, and exporting worldwide.
-
04
2025
Caliway Selected to Present CBL-514 Phase 2 Study Results for Dercum’s Disease at World Orphan Drug Congress USA 2025
CBL-514, Caliway’s novel small molecule drug, was selected for data presentation at the World Orphan Drug Congress USA 2025, highlighting its promising Phase 2 study results for Dercum’s Disease Treatment.
-
03
2025
Caliway Selected to Present CBL-514 Phase 2b Study Results at AMWC 2025 in Monaco
Caliway’s localized fat reduction drug, CBL-514, has been selected for presentation at the globally renowned AMWC Aesthetic & Anti-Aging Medicine World Congress under the "Body & Fat Treatment" session, highlighting CBL-0204 Phase 2b study results.
-
03
2025
Caliway’s CBL-514 Phase 2 Study (CBL-0202) Accepted for Publication in the Aesthetic Surgery Journal
CBL-514 Phase 2 study (CBL-0202) has been accepted for publication in Aesthetic Surgery Journal (ASJ).
-
02
2025
Caliway Biopharmaceuticals Added to MSCI World Small Cap Index, Reinforcing Global Standing
Caliway has been added to the MSCI World Small Cap Index, as announced today by MSCI (Morgan Stanley Capital International) in its latest quarterly review.
-
02
2025
Caliway Announces CBL-514 Second Phase 2b Study Results (CBL-0205) Met Endpoints
Caliway announced today that CBL-514’s second Phase 2b clinical study (CBL-0205) successfully met its primary and all critical secondary efficacy endpoints.
